REVIVA PHARMACEUTICALS HOLDINGS, INC.
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for central nervous system, inflammatory, and cardiometabolic diseases using a chemical genomics-driven technology platform. The company's lead drug candidate, brilaroxazine (RP5063), is in Phase 3 clinical development for schizophrenia and preclinical or clinical development for multiple neuropsychiatric, inflammatory, and respiratory indications including bipolar disorder, depression, ADHD, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. The company's second candidate, RP1208, is a novel triple reuptake inhibitor in preclinical development for depression and obesity.
Summary from 10-K filed 2026-03-30
Frequently asked questions
What is REVIVA PHARMACEUTICALS HOLDINGS, INC.'s CIK number?
REVIVA PHARMACEUTICALS HOLDINGS, INC.'s SEC CIK number is 0001742927 (1742927). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find REVIVA PHARMACEUTICALS HOLDINGS, INC.'s SEC filings?
All of REVIVA PHARMACEUTICALS HOLDINGS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.